Lactulose

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Retrieved on: 
화요일, 4월 30, 2024
Pain, FDA, Omeprazole, Fungal infection, Gastroenterology, Lactulose, PIN, Skin, Clarithromycin, Nausea, Hyponatremia, Infection, Paracetamol, Amoxicillin, Cardiomyopathy, Duchenne muscular dystrophy, Helicobacter pylori, Vomiting, Patient, Idiopathic pulmonary fibrosis, Constipation, Granisetron, Multimedia, Health, Acetylcysteine, Fever, Ibuprofen

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.

Key Points: 
  • NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
  • A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 2월 27, 2024
Fever, Ibuprofen, Clarithromycin, PIN, Lactulose, Multimedia, FDA, Acetylcysteine, Pain, Omeprazole, Granisetron, Amoxicillin, Idiopathic pulmonary fibrosis, Skin, Nausea, Vomiting, Constipation, Duchenne muscular dystrophy, Cardiomyopathy, Fungal infection, Hyponatremia, Paracetamol, Health, Patient, Helicobacter pylori, Infection, Gastroenterology

NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.

Key Points: 
  • NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.
  • A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 10월 31, 2023
Gastroenterology, Duchenne muscular dystrophy, Ibuprofen, FDA, Constipation, Clarithromycin, Granisetron, PIN, Hyponatremia, Lactulose, Vomiting, Omeprazole, Cardiomyopathy, Fungal infection, Skin, Infection, Health, Nausea, Multimedia, Helicobacter pylori, Fever, Acetylcysteine, Paracetamol, Pain, Patient, Amoxicillin, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Vaccine, Online shopping

NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023.

Key Points: 
  • NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023.
  • A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 8월 1, 2023
Idiopathic pulmonary fibrosis, Lactulose, Gastroenterology, Fever, Acetylcysteine, Constipation, Hyponatremia, Multimedia, Duchenne muscular dystrophy, Pain, Vomiting, Helicobacter pylori, PIN, Patient, Paracetamol, Amoxicillin, Call Me, Omeprazole, Granisetron, Nausea, Fungal infection, Ibuprofen, Infection, Cardiomyopathy, FDA, Health, Clarithromycin, Skin, Pharmaceutical industry, Vaccine, Online shopping

NASHVILLE, Tenn., Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023.

Key Points: 
  • NASHVILLE, Tenn., Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023.
  • A conference call will be held on Aug. 8 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 5월 2, 2023
Psoriatic arthritis, Lactulose, Gastroenterology, Fever, Acetylcysteine, Constipation, Methotrexate, Hyponatremia, Multimedia, Pain, Vomiting, Helicobacter pylori, PIN, Patient, Paracetamol, Amoxicillin, Systemic-onset juvenile idiopathic arthritis, Omeprazole, Nausea, Fungal infection, Ibuprofen, Infection, FDA, Health, Clarithromycin, Skin, Pharmaceutical industry, Vaccine, Online shopping

NASHVILLE, Tenn., May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023.

Key Points: 
  • NASHVILLE, Tenn., May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023.
  • A conference call will be held on May 9 at 4:30 p.m. Eastern Time, to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care.

Global Hepatic Encephalopathy Therapeutics Market Report 2023: Players Include Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline and Pfizer - ResearchAndMarkets.com

Retrieved on: 
수요일, 4월 19, 2023
Health, Pharmaceutical, Myenteric plexus, Seizure, Rifaximin, Hepatitis, Liver function tests, Therapy, Prevalence, Probiotic, Liver, Liver disease, Public, Anxiety, NORD, USFDA, Hepatic encephalopathy, Lactulose, Nutrient, Brain, National Organ Transplant Act of 1984, Thiamine, Acute liver failure, Plasma, Rare, Acetic acid, Patient, Ammonia, Lethargy, Confusion, Diagnosis, Personality, Cirrhosis, Disease, Vaccine, Dietary supplement

If effectively diagnosed, hepatic encephalopathy occurs in almost two-thirds of the patients suffering from liver cirrhosis.

Key Points: 
  • If effectively diagnosed, hepatic encephalopathy occurs in almost two-thirds of the patients suffering from liver cirrhosis.
  • Hepatic encephalopathy is categorized into 3 types Type A (acute liver failure), Type B (portal systemic bypass without liver disease), and Type C (liver cirrhosis).
  • The clinical manifestation associated with hepatic encephalopathy is confusion, anxiety, lethargy, seizures, confused speech, personality changes, and poor body movements.
  • In 2010 the USFDA approved Rifaximin for the treatment of hepatic encephalopathy by acting on the microorganisms in the intestinal tract producing ammonia.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS

Retrieved on: 
화요일, 2월 28, 2023
Skin, Infection, Helicobacter pylori, Pain, Rheumatology, Fever, Vomiting, Gastroenterology, Acetylcysteine, FDA, Patient, Paracetamol, Methotrexate, Systemic-onset juvenile idiopathic arthritis, Nausea, Health, Lactulose, PIN, Multimedia, Amoxicillin, Psoriatic arthritis, Omeprazole, Hyponatremia, Clarithromycin, Constipation, Fungal infection, Ibuprofen, Vaccine, Pharmaceutical industry, Online shopping

NASHVILLE, Tenn., Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023.

Key Points: 
  • NASHVILLE, Tenn., Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023.
  • A conference call will be held March 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is the largest biopharmaceutical company founded and headquartered in the Mid-South and is focused on the delivery of high-quality, prescription brands designed to improve patient care.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS

Retrieved on: 
화요일, 11월 1, 2022
Subclinical infection, Infection, Rheumatology, Pain, Omeprazole, Health, Gastroenterology, Paracetamol, Nausea, Vomiting, PIN, Clarithromycin, Juvenile idiopathic arthritis, Hyponatremia, Ibuprofen, NASDAQ, FDA, Skin, Helicobacter pylori, Acetylcysteine, Patient, Multimedia, Fever, Lactulose, Psoriatic arthritis, Amoxicillin, Constipation, Pharmaceutical industry, Vaccine, Online shopping, Telavancin

NASHVILLE, Tenn., Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8, 2022.

Key Points: 
  • NASHVILLE, Tenn., Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8, 2022.
  • A conference call will be held Nov. 8 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is the largest biopharmaceutical company founded and headquartered in the Mid-South and is focused on the delivery of high-quality, prescription brands designed to improve patient care.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS

Retrieved on: 
화요일, 8월 2, 2022
Lactulose, Helicobacter pylori, PIN, Juvenile idiopathic arthritis, Subclinical infection, Skin, Fever, Health, Amoxicillin, Ibuprofen, Infection, Psoriatic arthritis, Rheumatology, Gastroenterology, Multimedia, NASDAQ, Acetylcysteine, Constipation, Omeprazole, FDA, Nausea, Patient, Hyponatremia, Pain, Vomiting, Clarithromycin, Paracetamol, Pharmaceutical industry, Vaccine, Online shopping, Telavancin

NASHVILLE, Tenn., Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022.

Key Points: 
  • NASHVILLE, Tenn., Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022.
  • A conference call will be held Aug. 9 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is the largest biopharmaceutical company founded and headquartered in the Mid-South and is focused on the delivery of high-quality, prescription brands designed to improve patient care.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS

Retrieved on: 
화요일, 5월 3, 2022
Vomiting, Amoxicillin, Hyponatremia, Pain, Lactulose, Omeprazole, Health, NASDAQ, Gastroenterology, Acetylcysteine, Paracetamol, Subclinical infection, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Patient, Fever, Helicobacter pylori, FDA, Psoriatic arthritis, Rheumatology, Skin, Multimedia, Infection, Conference, Juvenile idiopathic arthritis, Ibuprofen, Constipation, Nausea, Clarithromycin, Pharmaceutical industry, Vaccine, Online shopping, Telavancin

NASHVILLE, Tenn., May 3, 2022 /PRNewswire/ --Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2022 financial results and provide a company update after the market closes on Tuesday, May 10, 2022.

Key Points: 
  • NASHVILLE, Tenn., May 3, 2022 /PRNewswire/ --Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2022 financial results and provide a company update after the market closes on Tuesday, May 10, 2022.
  • A conference call and live internet webcast will be held on May 10 at 4:30 p.m. Eastern Time to discuss the results.
  • To participate in the call, please dial (877) 303-1298 (for U.S. callers) or (253) 237-1032 (for international callers).
  • Cumberland Pharmaceuticals is the largest biopharmaceutical company founded and headquartered in the Mid-South and is focused on the delivery of high-quality, prescription brands designed to improve patient care.